  A novel 2,8-disubstituted-1,5-naphthyridine hit compound stemming from the open access Medicines for Malaria<disease> Venture Pathogen Box formed a basis for a hit-to-lead medicinal chemistry program. Structure-activity relationship investigations resulted in compounds with potent antiplasmodial activity against both chloroquine sensitive ( NF54) and multidrug resistant ( K1) strains of the human malaria<disease> parasite Plasmodium<pathogen> falciparum<pathogen> In the humanized P.<pathogen> falciparum<disease> mouse efficacy model , one of the frontrunner compounds showed in vivo efficacy at an oral dose of 4 × 50 mg · kg